Elon Musk renews his criticism of Trump's big bill as Senate Republicans scramble to pass it
Elon Musk attends a news conference with President Donald Trump in the Oval Office of the White House, May 30, 2025, in Washington. (AP Photo/Evan Vucci, File)
WASHINGTON — Elon Musk on Saturday doubled down on his distaste for U.S. President Donald Trump's sprawling tax and spending cuts bill, arguing the legislation that Republican senators are scrambling to pass would kill jobs and bog down burgeoning industries.
'The latest Senate draft bill will destroy millions of jobs in America and cause immense strategic harm to our country,' Musk wrote on X on Saturday ahead of a procedural U.S. Senate vote to open debate on the nearly 1,000-page bill. 'It gives handouts to industries of the past while severely damaging industries of the future.'
The Tesla and SpaceX CEO, whose birthday is also Saturday, later posted that the bill would be 'political suicide for the Republican Party.'
The criticisms reopen a recent fiery conflict between the former head of the U.S. Department of Government Efficiency and the administration he recently left. They also represent yet another headache for Republican Senate leaders who have spent the weekend working overtime to get the legislation through their chamber so it can pass by Trump's Fourth of July deadline.
Musk has previously made his opinions about Trump's 'big, beautiful bill' clear. Days after he left the federal government last month with a laudatory celebration in the Oval Office, he blasted the bill as 'pork-filled' and a 'disgusting abomination.'
'Shame on those who voted for it: you know you did wrong. You know it,' he wrote on X earlier this month. In another post, the wealthy GOP donor who had recently forecasted that he'd step back from political donations threatened to fire lawmakers who 'betrayed the American people.'
When Trump clapped back to say he was disappointed with Musk, back-and-forth fighting erupted and quickly escalated. Musk suggested without evidence that Trump, who spent the first part of the year as one of his closest allies, was mentioned in files related to sex abuser Jeffrey Epstein.
Musk ultimately tried to make nice with the administration, saying he regretted some of his posts that 'went too far.' Trump responded in kind in an interview with The New York Post, saying, 'Things like that happen. I don't blame him for anything.'
It's unclear how Musk's latest broadsides will influence the fragile peace he and the president had enjoyed in recent weeks. The White House didn't immediately respond to a request for comment.
Musk has spent recent weeks focused on his businesses, and his political influence has waned since he left the administration. Still, the wealthy businessman poured hundreds of millions of dollars into Trump's campaign in 2024, demonstrating the impact his money can have if he's passionate enough about an issue or candidate to restart his political spending.
Though he was silent on Musk, Trump laid on pressure and lashed out strongly at Republican holdouts in the Senate as lawmakers spent hours taking a procedural vote during a rare Saturday evening session. He accused Sen. Thom Tillis of North Carolina of seeking publicity with his no vote and threatened to campaign against the senator's reelection.
The legislation narrowly cleared its test vote in the Senate late Saturday evening, allowing senators to begin debate.
Ali Swenson, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
18 minutes ago
- Globe and Mail
AMD is Pursuing Product Line Expansion: Will Margins Sustain?
Advanced Micro Devices AMD is benefiting from sustained gross margin expansion, driven by a richer mix of high-end Ryzen processors within its client segment and a higher percentage of data center product sales, leading to expanded gross margins for the fifth consecutive quarter. In the first quarter of 2025, Non-GAAP gross margin expanded 140 basis points (bps) on a year-over-year basis to 53.7%. Strong demand for high-end Ryzen CPUs in both gaming and commercial PCs is contributing to a favorable product mix that supports margin expansion. The data center segment, which includes EPYC CPUs and Instinct GPUs, continues to deliver strong revenue growth and higher margins, driven by increased adoption by hyperscalers and enterprise customers. AMD's latest Ryzen CPUs, particularly those based on the Zen 5 architecture, have seen strong demand, especially for gaming and high-performance desktops and laptops. The launch of new products, like the Ryzen 9 9950 X3D, helped set sellout records and boosted the client segment. The sales of higher-end products, including Ryzen processors for both desktop and mobile, led to higher average selling prices, which continue to positively impact gross margins. AMD expects gross margins to remain strong as demand for its high-performance products continues to grow. For the second quarter of 2025, AMD has guided a gross margin of approximately 54%, excluding an $800 million inventory-related charge tied to the MI308 export controls. Advanced Micro Devices Face Stiff Competition AMD faces intense competition from NVIDIA NVDA and Intel Corporation INTC in the data center and client segments. While both NVIDIA and Intel Corporation have recently seen declines in gross margin, AMD continues to expand its margin through a favorable product mix and strong demand for high-end offerings. NVIDIA's gross margins declined in the first quarter of fiscal 2026, with non-GAAP gross margin slipping 12.5 percentage points sequentially to 61%. This decline was primarily due to a $4.5 billion charge related to H20 inventory and purchase commitments that became unsellable following the new U.S. export restrictions on H20 chip shipments to China. Intel Corporation's non-GAAP gross margin declined to 39.2% from 45.1% a year ago in the first quarter of 2025. Margins were significantly impacted by impairment charges and restructuring costs associated with a structural and operational realignment across the company. AMD's Share Price Performance, Valuation and Estimates Advanced Micro Device shares have gained 19% year to date, outperforming the broader Zacks Computer & Technology sector's return of 6.1%. AMD Stock Performance AMD stock is trading at a premium, with a forward 12-month Price/Sales of 6.78X compared with the industry's 3.87X. AMD has a Value Score of F. AMD Valuation The Zacks Consensus Estimate for second-quarter 2025 earnings is currently pegged at 54 cents per share, implying an 8.4% decline over the past 30 days. This indicates a 21.74% decrease year over year. The consensus mark for 2025 earnings is pegged at $3.92 per share, which has declined 2.4% over the past 30 days, suggesting 18.43% year-over-year growth. AMD currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report
Globe and Mail
18 minutes ago
- Globe and Mail
Constellation Brands, Nike and FedEx are part of Zacks Earnings Preview
For Immediate Release Chicago, IL – June 30, 2025 – releases the list of companies likely to issue earnings surprises. This week's list includes Constellation Brands STZ, Nike NKE and FedEx FDX. Looking Ahead to Q2 Earnings Season The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will be the lowest earnings growth pace since the +4.3% growth rate in 2023 Q3. We have been regularly flagging in recent weeks that 2025 Q2 earnings estimates have been steadily decreasing. As we have been consistently flagging, earnings estimates took a renewed hit at the start of Q2, following the early April tariff announcement. This was particularly notable for Q2, but estimates for the subsequent periods were also trimmed. While the revisions trend has notably stabilized in recent weeks, the magnitude of cuts to 2025 Q2 estimates since the start of the period is larger and more widespread compared to what we have become accustomed to seeing in the post-COVID period. Since the start of April, Q2 earnings estimates have declined for 13 of the 16 Zacks sectors (Aerospace and Utilities are the only sectors whose estimates have increased), with the biggest cuts to Conglomerates, Autos, Transportation, Energy, Basic Materials, and Construction sectors. Estimates for the Tech and Finance sectors, the largest earnings contributors to the S&P 500 index, accounting for more than 50% of all index earnings, have also been cut since the quarter got underway. But as we have been pointing out in recent weeks, the revisions trend for the Tech sector has notably stabilized in recent weeks. We see this same trend at play in annual estimates as well. The chart below shows the Tech sector's evolving earnings expectations for full-year 2025 A likely explanation for this stabilization in the revisions trend is the easing in the tariff uncertainty after the more punitive version of the tariff regime was delayed. Analysts began revising their estimates downward in the immediate aftermath of the early April tariff announcements but appear to have since concluded that those punitive tariff levels are unlikely to be levied, helping to stabilize the revisions trend. In terms of S&P 500 index 'EPS', these growth rates approximate to $254.14 for 2025 and $287.31 for 2026. Q2 Earnings Season Scorecard As noted earlier, we have already seen fiscal May-quarter results from 18 S&P 500 members, which we count as part of our Q2 tally. Total earnings for these 18 index members that have reported results are up +3.1% from the same period last year on +6.5% revenue gains, with 83.3% of the companies beating EPS estimates and 88.9% of them beating revenue estimates. We are not drawing any conclusions from these results, given the small sample size at this stage. But we nevertheless wanted to put these early results in a historical context. We have less than a dozen companies on deck to report results this holiday-shortened week, including Constellation Brands from the S&P 500 index. Constellation produces alcoholic beverages, with a portfolio of beer-heavy products, including Modelo, Corona, and others. Constellation shares have been under pressure this year, with the stock down -27% in the year-to-date period and lagging the broader market's +3.8% gain. Constellation's core product, Modelo, is heavily indexed to Hispanic consumers, with over 50% of the brand's sales coming from this demographic group. While the labor market remains strong, consumption trends of this demographic group have been weighed down by affordability issues. Aluminum tariffs are another headwind for Constellation Brands, given the company's exposure to the industrial metal for beer cans. Among the notable recent earnings releases, market participants were pleased with the Nike announcement but were less enthusiastic about the FedEx report. Both companies have been big-time laggards lately, with Nike shares down -4.8% this year, even after the big post-release jump, and FedEx shares are down -18.5%. While there were undoubtedly a few 'green shoots' in the Nike release, the stock's strong positive reaction is more a function of how low expectations had been coming into the release rather than truly impressive numbers. Nike still faces multiple challenges, including margin pressure, a stagnant product portfolio, operational challenges in China (accounting for approximately 15% of total sales), and significant tariff exposure. We should note, however, that both Nike and FedEx beat top- and bottom-line consensus estimates. For a detailed view of the evolving earnings picture, please check out our weekly Earnings Trends report here >> >> A Closer Look At Q2 Earnings: What Can Investors Expect? Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> NIKE, Inc. (NKE): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report
Globe and Mail
18 minutes ago
- Globe and Mail
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
For CVS Health CVS, the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company's Pharmacy Benefit Manager ('PBM'), CVS Caremark, will list Wegovy — the flagship GLP-1-based weight loss medication from Novo Nordisk NVO — on its largest commercial template formularies. Encouragingly, CVS plans to pair these medications with additional lifestyle clinical support as part of its Weight Management program. In parallel, the company is removing Eli Lilly 's LLY GLP-1 medication, Zepbound, from its coverage, reflecting a broader strategy to reasonably balance access and affordability amid soaring demand for these drugs. Through the NVO partnership, CVS aims to significantly expand Wegovy's reach at a more affordable price. The move mirrors its past success in driving the adoption of Humira biosimilars, including Cordavis — its branded version — which now holds the largest U.S. market share. The highly impactful GLP-1 medications were initially launched at exorbitant prices, forcing many to exclude them from their benefits. PBMs like CVS Caremark negotiate drug prices on behalf of health plans and often receive manufacturer rebates in return for formulary placements of medications. That said, the combination of GLP-1 medications and the wrap-around support through its Weight Management program leads to better outcomes, even greater than the pre-program results. Recent compelling data revealed that Caremark clients using the program spent up to 26% less on GLP-1 medications for weight loss, with 92% of participating plan members expressing satisfaction after six months in the program. Updates From CVS Peers, UNH and ELV Another leading PBM, UnitedHealth Group 's (UNH) Optum Rx, currently covers both Wegovy and Zepbound on its standard commercial formularies for weight loss, with the formulary remaining unchanged for July 1. In a recent update, Optum Rx noted that it is eliminating up to 25% of reauthorizations, which is equal to more than 10% of overall pharmacy prior authorizations, to make prescription drugs more affordable and the pharmacy experience simpler for consumers with chronic conditions. Elevance Health ELV -owned PBM, Carelon Rx, also has a digital weight management program supporting members on their weight loss journeys, including those who utilize GLP-1 medications. Growth in CarelonRx product revenues was a key contributor to Elevance Health's 15% operating revenue growth in the first quarter of 2025. CVS Stock Outpaces Peers, P/S Remains Attractive Year to date, CVS Health shares have rallied 48.8% against the industry's 1.3% dip, ELV's 1% gain and a steep 40.7% loss for UNH. CVS shares are trading at a forward three-year price-to-sales of 0.21X, lower than the industry average of 0.40X. The stock carries a Value Score of A. CVS Stock Estimate Trend The consensus estimate for CVS Health's 2025 earnings has been trending upward. However, the same for 2026 remains mixed. CVS stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. (We are reissuing this article to correct a mistake. The original article, issued on June 24, 2025, should no longer be relied upon.) Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis Report
